Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970032 | 1.00 | TAAR1 (0.53) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL2920753 | 1.00 | TAAR1 (0.53) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL15203095 | 0.89 | ACE (0.47) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL24153337 | 0.89 | ACE (0.47) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL17167138 | 0.84 | CAPN1 (0.60) | CAPN1ACECTSB | |
| SCHEMBL21654011 | 0.83 | CAPN1 (0.49) | TAAR1SLC18A2SIGMAR1CAPN1MEN1 | |
| SCHEMBL13599518 | 0.82 | CAPN1 (0.38) | CAPN1ACE | |
| SCHEMBL10167782 | 0.82 | ACE (0.53) | TAAR1CAPN1MEN1KMT2AACE | |
| SCHEMBL13489139 | 0.82 | ACE (0.53) | TAAR1CAPN1MEN1KMT2AACE | |
| SCHEMBL12803090 | 0.82 | ACE (0.53) | TAAR1CAPN1MEN1KMT2AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| US-5140009-A | Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders | TAP PHARMACEUTICALS, INC. (US) | 1992-08-18 | — | — | US | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2021262731-A2 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-10954269-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2021-03-23 | — | — | US | disclosed |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-05-23 | — | — | US | disclosed |
| WO-2015040235-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2015-03-26 | — | — | WO | disclosed |
| US-6777535-B1 | USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS | ABBOTT LABORATORIES | 2004-08-17 | — | — | US | disclosed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | disclosed |
| EP-0863916-B1 | POLYFLUOROALKYL TRYPTOPHAN TRIPEPTIDE THROMBIN INHIBITORS | AVENTIS PHARMA INC (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1012165-A1 | PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N- 1- 3- (AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE | Aventis Pharmaceuticals Inc. (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1997035874-A1 | PROCESS FOR THE PREPARATION OF N-METHYL-D-PHENYLALANYL-N-[1-[3-[(AMINOIMINOMETHYL)AMINO]PROPYL]-3,3-DIFLUORO-2-OXOHEXYL]-L-PROLINAMIDE | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | TAAR1 4814/4885SLC18A2 1679/4885SIGMAR1 3195/4885 |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | TAAR1 2337/4885SLC18A2 4192/4885SIGMAR1 1907/4885 |
| US-10954269-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | TAAR1 2337/4885SLC18A2 4192/4885SIGMAR1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.